Science Explorer Interactive view Map
Company · Didcot · United Kingdom

Karus Therapeutics (United Kingdom)

karustherapeutics.comROR OpenAlex
Research works
41
▼ 67% vs 2013–17
Citations
795
19.5 per fractional work
Top-10% rate
14.8%
record average 16.5%
Open access
20%
world 28%

Not ranked overall: Karus Therapeutics (United Kingdom) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at Karus Therapeutics (United Kingdom)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Gene Expression, Cancer, Transcriptional Regulation, Epigenetic Regulation, HDAC Inhibitors, Histone Deacetylases and PET Imaging.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Therapy9▲ 33×8 topics
  2. Cancer4▲ 6.8×9 topics
  3. Gene Expression4▲ 15×3 topics
  4. Epigenetic Regulation3▲ 39×2 topics
  5. HDAC Inhibitors3▲ 426×1 topic
  6. Histone Deacetylases3▲ 426×1 topic
  7. Transcriptional Regulation3▲ 34×3 topics
  8. PET Imaging3▲ 35×3 topics
  9. BET Bromodomains3▲ 355×1 topic
  10. PROTACs3▲ 355×1 topic
  11. Cell Growth3▲ 206×2 topics
  12. Metabolism3▲ 11×3 topics
  13. Signaling3▲ 59×2 topics
  14. Immunosuppression3▲ 57×3 topics
  15. Oxidative Stress2▲ 3.3×8 topics
  16. PI3K/AKT pathway2▲ 283×1 topic
  17. Tumor Microenvironment2▲ 17×2 topics
  18. mTOR2▲ 283×1 topic
  19. Fibroblast Activation Protein2▲ 115×1 topic
  20. N-terminal Acetylation2▲ 115×1 topic
  21. Rituximab2▲ 32×2 topics
  22. Prognostic Factors2▲ 10×4 topics
  23. Metastatic Breast Cancer2▲ 65×2 topics
  24. Tumor Suppression2▲ 36×2 topics
  25. Apoptosis2▲ 9.4×2 topics
  26. Chronic Lymphocytic Leukemia2▲ 76×1 topic
  27. Genomic Aberrations2▲ 76×1 topic
  28. Mutation1▲ 22×2 topics
  29. Cell Cycle1▲ 57×1 topic
  30. Immunotherapy1▲ 5.0×6 topics
  31. p531▲ 75×1 topic
  32. Cell Cycle Control1▲ 120×2 topics
  33. Clinical Trials1▲ 4.8×4 topics
  34. Proteasome Inhibitors1▲ 41×2 topics
  35. Targeted Therapy1▲ 14×4 topics
  36. Breast Cancer1▲ 9.7×1 topic
  37. CDK4/6 Inhibitors1▲ 171×1 topic
  38. Lymphoma1▲ 18×3 topics
  39. Pathogenesis1▲ 4.6×4 topics
  40. Genetic Characterization1▲ 44×2 topics

Which research topics does Karus Therapeutics (United Kingdom) publish most on?

By volume in 2022–2025: Protein Degradation and Inhibitors, Fibroblast Growth Factor Research, Peptidase Inhibition and Analysis and Redox biology and oxidative stress.

Protein Degradation and …0Protein Degradation and Inhibitors: 0 fractional worksFibroblast Growth Factor…0Fibroblast Growth Factor Research: 0 fractional worksPeptidase Inhibition and…0Peptidase Inhibition and Analysis: 0 fractional worksRedox biology and oxidat…0Redox biology and oxidative stress: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksLung Cancer Research Studies: 0 fractional worksHistone Deacetylase Inhi…0Histone Deacetylase Inhibitors Research: 0 fractional worksNeuroblastoma Research a…0Neuroblastoma Research and Treatments: 0 fractional worksNeuroendocrine Tumor Res…0Neuroendocrine Tumor Research Advances: 0 fractional worksUbiquitin and proteasome…0Ubiquitin and proteasome pathways: 0 fractional works
Molecular BiologyOncologyPulmonary and Respiratory MedicineNeurology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Protein Degradation and Inhibitors Molecular Biology 0 works
  2. 2 Fibroblast Growth Factor Research Molecular Biology 0 works
  3. 3 Peptidase Inhibition and Analysis Oncology 0 works
  4. 4 Redox biology and oxidative stress Molecular Biology 0 works
  5. 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  6. 6 Lung Cancer Research Studies Oncology 0 works
  7. 7 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
  8. 8 Neuroblastoma Research and Treatments Neurology 0 works
  9. 9 Neuroendocrine Tumor Research Advances Epidemiology 0 works
  10. 10 Ubiquitin and proteasome pathways Molecular Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available20.3%not open79.7%

World: 28% of research is openly available.

with international co-authors28.7%domestic only71.3%

World: 19% is written across borders.

How has Karus Therapeutics (United Kingdom)'s research output changed?

Output in 2018–2022 was 67% lower than in 2013–2017.

199520002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Didcot

All research institutions in Didcot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.